Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | USP5 | P45974 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501789 | 0.88 | TAAR1 (0.37) | RAB9AUSP5NPC1SMN1; SMN2POLB | |
| SCHEMBL26501780 | 0.87 | USP5 (0.47) | RAB9AUSP5NPC1SMN1; SMN2POLB | |
| SCHEMBL26501785 | 0.83 | RAB9A (0.36) | RAB9AUSP5NPC1SMN1; SMN2POLB | |
| SCHEMBL26501786 | 0.83 | RAB9A (0.36) | RAB9AUSP5NPC1SMN1; SMN2POLB | |
| SCHEMBL26501676 | 0.82 | PANK3 (0.39) | PANK3ACHEP2RX3P2RX2L3MBTL1 | |
| SCHEMBL26501699 | 0.80 | TSHR (0.44) | RAB9ANPC1SMN1; SMN2POLBLMNA | |
| SCHEMBL26501783 | 0.75 | NPC1 (0.51) | RAB9ANPC1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL26501655 | 0.75 | DHFR (0.35) | PANK3LMNAESR1ESR2ABCB11 | |
| SCHEMBL26501796 | 0.74 | HDAC1 (0.35) | RAB9ANPC1SMN1; SMN2PANK3P2RX3 | |
| SCHEMBL26501740 | 0.74 | ALDH1A1 (0.35) | LMNAL3MBTL1ESR1ESR2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | RAB9A 3971/4885USP5 2517/4885NPC1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.